On August 14, 2018, Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) completed its June-announced acquisition of Anandia Laboratories Inc. in an all-stock transaction valued at $118 million pursuant to a court ordered plan of arrangement.
Anandia Laboratories is a world-leading cannabis-focused science company, specialized in genomics, metabolite profiling, plant breeding, disease characterization, and cultivar certification, as well as providing testing services to producers and patient-cultivators. The transaction is designed to enhance the biotech side of Aurora’s business—a key market differentiator—and is in line with the company’s vertical integration strategy and product development efforts.
Aurora Cannabis is one of the world’s largest and leading cannabis companies with sales and operations in 14 countries spanning five (5) continents.
McMillan LLP acted as counsel to Aurora Cannabis with a team led by Desmond (Des) Balakrishnan and comprised of Michael Reid, Morgan McDonald and Lindsay Dykstra (Business Law), with able assistance from Peter Botz (Tax), Herb Ono and Joni Liew (US Securities), Marina Tran, Venice Chan and Brandon Deans (Capital Markets), Peter Reardon and Natalie Cuthill (Litigation), Pablo Tseng (IP), and Cecilia Tsang and Nicole Burch (Corporate Services).
Blake, Cassels & Graydon LLP acted as counsel for Anandia Laboratories with a team led by Steven McKoen and Joseph Garcia and that included Lauren Akin, Riley Graydon and Ryan Everett (M&A), Bill Maclagan and Matt Weaver (Tax), Sean Boyle and Alexandra Luchenko (Litigation), and Michael Howcroft (Employment).